Comparison of Mean VEGF-A Expression Between Acute Ischemic Stroke Patients and Non-Ischemic Stroke Subject by Setyopranoto, Ismail et al.
 _______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2019 Mar 15; 7(5):747-751.                                                                                                                                                        747 
 
ID Design Press, Skopje, Republic of Macedonia 
Open Access Macedonian Journal of Medical Sciences. 2019 Mar 15; 7(5):747-751. 
https://doi.org/10.3889/oamjms.2019.175 
eISSN: 1857-9655 
Clinical Science 
 
 
  
 
Comparison of Mean VEGF-A Expression Between Acute 
Ischemic Stroke Patients and Non-Ischemic Stroke Subjects 
 
 
Ismail Setyopranoto
1
, Ahmad Hamim Sadewa
2
, Samekto Wibowo
1
, I Putu Eka Widyadharma
3*
 
 
1
Department of Neurology, Faculty of Medicine, Universitas Gadjah Mada and Dr Sardjito General Hospital, Yogyakarta, 
Indonesia; 
2
Department of Biochemistry, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia; 
3
Department of Neurology, Faculty of Medicine, Udayana University and Sanglah General Hospital, Bali, Indonesia 
 
Citation: Setyopranoto I, Sadewa AH, Wibowo S, 
Widyadharma IPE. Comparison of Mean VEGF-A 
Expression Between Acute Ischemic Stroke Patients and 
Non-Ischemic Stroke Subjects. Open Access Maced J 
Med Sci. 2019 Mar 15; 7(5):747-751. 
https://doi.org/10.3889/oamjms.2019.175 
Keywords: Acute ischemic stroke; Hypoxia; Expression; 
VEGF-A 
*Correspondence: I Putu Eka Widyadharma. Department 
of Neurology, Faculty of Medicine, Udayana University 
and Sanglah General Hospital, Bali, Indonesia. E-mail: 
eka.widyadharma@unud.ac.id 
Received: 13-Jan-2019; Revised: 17-Feb-2019; 
Accepted: 18-Feb-2019; Online first: 13-Mar-2019 
Copyright: © 2019 Ismail Setyopranoto, Ahmad Hamim 
Sadewa, Samekto Wibowo, I Putu Eka Widyadharma. 
This is an open-access article distributed under the terms 
of the Creative Commons Attribution-NonCommercial 4.0 
International License (CC BY-NC 4.0) 
Funding: This research did not receive any financial 
support 
Competing Interests: The authors have declared that no 
competing interests exist 
 
 
 
 
 
 
 
 
 
 
Abstract 
BACKGROUND: Glucose and oxygen supply to neurons are disrupted during acute ischemic stroke, resulting in 
hypoxia. This event, in turn, activates the transcription of hypoxia-inducible factor (HIF-1), which is responsible for 
activating genes responsible for angiogenesis, including vascular endothelial growth factor (VEGF). VEGF and 
their receptor systems exert complex mechanisms of angiogenesis, including the stimulator, inhibitors, angiogenic 
and modulator. VEGF-A is the primary regulator of angiogenesis, both during physiological and pathological 
conditions. Nevertheless, the role of VEGF on the prognosis of hypoxia remains controversial. 
AIM: The purpose of this study was to address if there is any difference between the mean expression of VEGF-A 
between acute ischemic patients and non-ischemic stroke subjects.  
METHODS: This was an observational study with a cross-sectional design, the population in this research is the 
acute ischemic stroke patients and non-ischemic stroke subjects, which were admitted on Emergency Room and 
later treated in the Stroke Unit, Dr Sardjito General Hospital, Yogyakarta, Indonesia. Subjects were recruited 
using the purposive method, yielding a total of 64 subjects on both groups. Diagnosis of acute ischemic stroke 
was established using a head CT scan. Patients who meet the inclusion criteria and willing to participate in the 
study were asked to provide informed consent. Laboratory analysis was conducted during the first 24 hours after 
being treated at Stroke Unit, Dr Sardjito General Hospital, Yogyakarta, Indonesia, with venous blood was 
withdrawn VEGF-A levels between acute ischemic stroke and non-ischemic stroke subjects were subsequently 
compared. Categorical variables (including gender) were tested using either chi-square or Fisher exact test. 
Interval data was examined using student t-test if data distribution was normal.  
RESULTS: As many as 35 acute ischemic stroke and 35 non-ischemic stroke patients were included in the study, 
among whom were 18 men (51.43%) and 17 women (48.57%) among stroke patients and 21 (60%) men and 14 
(40%) women among subjects without stroke. The average of the subject's age on stroke and non-ischemic 
stroke group was 58.51 and 48.57 years old. VEGF-A levels were significantly higher in the non-stroke group 
(561.77 ± 377.92) compared with stroke group (397.78 ± 181.53) with p = 0.02.  
CONCLUSION: expression of VEGF-A in acute ischemic stroke group was lower when compared with the non-
stroke group. 
 
 
 
 
 
 
Introduction 
 
VEGF-A is the primary regulator of 
angiogenesis, both during physiological and 
pathological conditions, including those related to 
malignancy or hypoxia of any cause including acute 
ischemic stroke [1]. Hypoxia triggers smooth muscle 
cell proliferation and endothelial cells to form new 
blood vessels so that it will improve the function of 
oxygenation. Hypoxia activates several important 
genes and signal pathways under the condition above 
[2].
 
 
As a result of hypoxia, the gene will be 
controlled by the transcription of Hypoxia-Inducible 
Factor 1 (HIF-1). HIF-1 will activate genes responsible 
for angiogenesis, for example, Vascular Endothelial 
Growth Factor (VEGF) [3]. Oxygen functions as a 
regulator of VEGF production, hypoxia causes an 
increase in VEGF levels and returns to the baseline 
level within 24 hours, and then the cell returns to 
normoxia condition [4]. VEGF levels will be reduced in 
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hyperoxia in vitro and in vivo [5]. Nevertheless, the 
role of VEGF in hypoxia remains controversial, 
considering several studies showing different results. 
This study aims to prove that there are 
differences in the mean expression of the Vascular 
Endothelial Growth Factor-A (VEGF-A) between acute 
ischemic stroke patients with non-stroke patients.  
 
 
Material and Methods 
 
This was an analytical observational study. 
The inclusion criteria in this study were acute ischemic 
stroke patients both male and female, of 35 to 70 
years old, with a maximum 5-day duration between 
the time of the attack and hospital admission, (2) 
stroke onset was defined as the last time the patient 
was known by others in a healthy condition and had 
not shown any signs of neurological deficit, (3) the 
presence of one of the neurologic deficits are 
decreased consciousness, hemiparesis, seventh 
and/or eighth cranial nerve palsy,, dysarthria, aphasia, 
or hemianopsia, (4) proven acute ischemic stroke with 
head CT scan.  
The eligible criteria in this study were: (1) 
intracerebral haemorrhage patients or the space-
occupying process for other reasons, (2) any history 
of previous strokes.  
Non-ischemic stroke groups including non-
infectious low back pain patients who were treated in 
the Neurological Ward or general check-up patients 
who are known to have no degenerative abnormalities 
that have vascular influences, such as hypertension, 
diabetes mellitus or dyslipidemia, taken in the same 
period, both male and female.  
Subjects were recruited by a consecutive 
method, in which every new ischemic stroke patient 
who came through an Emergency Department and 
treated at the Stroke Unit Dr Sardjito General 
Hospital, who fulfilled the inclusion criteria and willing 
to participate in the study after being explained with 
the risks and benefits. All participants included in the 
study were asked for informed consent. 
These steps must be carried out until the 
specified sample size reaches the number of samples. 
The participants above' identity and characteristics 
were then recorded in the case form. 
History taking and physical examination of all 
included subjects were performed by a neurology 
resident and those who were suspected of having 
acute ischemic stroke underwent additional head CT 
scan.  
Laboratory analysis was carried out once, at 
24 hours after being treated at the Stroke Unit Dr 
Sardjito General Hospital, and blood was withdrawn 
from a vein, then VEGF-A levels were examined by 
ELISA method.  
Comparative analysis was made on subjects 
with acute ischemic stroke with non-stroke subjects 
concerning VEGF-A levels. The level of significance 
used is 0.05 or 95% confidence interval (p < 0.05), 
with 80% power. All statistical analyses were 
performed using SPSS for Windows version 20. 
 
 
Results 
 
This study began in August to December 
2011. A total of 11 subjects were not included in this 
study, among whom 8 of them refused to participate in 
the study and three subjects were excluded because 
of acute renal insufficiency. Seventy subjects, 
therefore, were included in the study, i.e., every 35 
subjects with acute ischemic stroke and non-ischemic 
stroke cases.s. The basic characteristics of the 
research subject were obtained through descriptive 
analysis.  
Of the total subjects in the stroke group based 
on sex, 18 (51.437%) subjects were of males, and 17 
(48.57%) subjects were of females. Subject 
comparison based on sex were then considered 
homogenous. In contrast, in the non-ischemic stroke 
group, there were more female than male subjects (21 
[60%] vs 14 [40%]). 
Table 1: Basic Characteristics of Research Subjects 
 Stroke Groups Non-Stroke Groups p 
Male 18 (51.43%) 14 (40.00%) - 
Female 17 (48.57%) 21 (60.00%) - 
Age (years) 58.51 ± 9.89 48.57 ± 11.36 - 
VEGF-A level 397.78 ± 181.53 561.77 ± 377.92 0.02 
 
Furthermore, based on the subjects' age, the 
average stroke group was 58.51 years old, higher 
than the non-ischemic stroke group with an average of 
48.57 years old. While VEGF-A levels were 
significantly higher in the non-ischemic stroke group, 
i.e.561.77 ± 377.92, compared to the stroke group 
(397.78 ± 181.53) with p = 0.02. 
 
 
Discussion 
 
VEGF-A levels in the stroke group were lower 
than that of non-ischemic stroke group. This result is 
different from other studies, in which VEGF-A levels 
were found at higher levels. For instance, in cases of 
malignancy, an increase in VEGF-A expression can 
be observed in lung adenocarcinoma, six colorectal 
carcinomas,
 
pancreatic carcinomas, breast carcinoma, 
and ovarian carcinoma [7], [8], [9], [10].  
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There are several explanations as to why in 
the stroke group there was a lower VEGF-A level 
compared with the non-ischemic stroke group. Stroke 
is caused by several potential risk factors associated 
with a decrease in VEGF levels, for example, elderly, 
diabetes mellitus and also the possibility of early 
complications of kidney failure, although the results of 
laboratory tests have not shown signs of kidney 
failure. Low serum albumin levels are often found in 
elderly patients. Hypoalbuminemia was reported in 
19% of stroke patients [11]. 
Furthermore, albumin significantly reduced 
VEGF expression during hypoxia [12]. 
Hypoalbuminemia is associated with 
endothelial dysfunction in all causes of death in 
patients with chronic kidney disease and 
cardiovascular mortality in terminal kidney disease 
patients. However, it is not yet clear whether 
endothelial dysfunction is a direct result of a decrease 
in albumin levels or due to other factors, such as 
chronic inflammation and dyslipidemia, and indeed it 
is often found in conditions associated with 
hypoalbuminemia [12]. 
In contrast to previous in vitro studies, in this 
study, we found that a decrease in VEGF-A levels is a 
response to hypoxia. An explanation might be related 
to the study of Lerman et al., in mice, by which the 
production of VEGF by fibroblasts in diabetic 
conditions-because of the presence of glucose 
intolerance-did not increase the regulation of VEGF 
under hypoxic conditions [14]. Hypoxia causes 
glucose intolerance in vivo, so in this study, VEGF 
production may be influenced by glucose intolerance, 
because stroke patients may have risk factors for 
diabetes mellitus [15].  
There is a study on changes in VEGF levels 
in the circulation which are likely to be influenced by 
glucose transporters, on the blood-brain barrier [16] 
[17]. Besides, VEGF also mediates the induction of 
endothelial fenestration, thus increasing the transport 
of small molecules such as sucrose and fluorescein to 
penetrate the blood-brain barrier [18], [19]. Based on 
these mechanisms on the blood-brain barrier, a 
decrease in VEGF after acute hypoxia can reduce 
glucose transfer across the blood-brain barrier which 
ultimately is neuroprotective.  
Furthermore, a decrease in VEGF-A levels in 
the stroke group compared with the non-ischemic 
stroke group might be partly explained by the fact that 
astroglial cells are the most abundant cells in the 
central nervous system and play an important role in 
the pathology of brain tissue. Although never proven 
directly, astrocytes are thought to have a 
neuroprotective role in protecting neurons from 
oxidative stress during a stroke. The hypothesis is 
based on the ability of astrocytes to act as a buffer, to 
transport and metabolise amino acids, glucose, and 
other important molecules, and also improve 
antioxidant regulation and free radical scavenger in 
the area of ischemia. Reactive gliosis is the response 
of the astrocytes at the time of central nervous system 
injury, including cerebral ischemia, and reactive 
astrocytes undergo changes in morphology and 
expression in various molecules [20]. 
Reported by Bareto et al., that although there 
is extensive cell proliferation, especially in microglia 
and neutrophils/monocytes at one week after the 
stroke, however, there are some adult astrocytes that 
re-enter into the cell cycle, and this is concentrated 
around the infarct area [21]. 
Astrocytes are known to be more resistant to 
oxidative stress than neurons and act as 
neuroprotectors through their ability to take potassium 
and glutamate and release mitogenic factors. But in 
response to injury, astrocytes will pull off its endfeet 
from the blood vessels, which will result in increased 
permeability, as well as due to proliferation, it will 
cause scars on the glial cells [22]. 
Hypoxia/ischemia causes activation of 
adaptive mechanisms and changes in gene 
expression in injured areas to counteract the 
pathological progression caused by inducing 
transcription of Hypoxia-Inducible Factor (HIF-1). The 
primary target of HIF-1 is a gene that plays a 
cytoprotective role, VEGF. Astrocytes can secrete 
VEGF under physiological conditions, and then 
hypoxia will induce both mRNA and protein [23]. 
Other factors also cause a decrease in VEGF 
expression due to hypoxia, namely Glia Cell-Derived 
Conditioned Medium (CM) [24]. Furthermore, it was 
explained that hypoxia which causes astrocytes could 
inhibit an increase in VEGF mRNA expression 
Conditioned Medium (CM) or C6 CM glioma cells. 
During normoxia, CM astrocytes and C6 CM glioma 
cells do not change the expression of VEGF mRNA. 
Thus hypoxia which causes an increase in VEGF 
protein will be inhibited by CM glia cells.  
Studies are documenting the potential of 
VEGF therapy to repair peripheral neuropathy in 
diabetes [25]. Other studies reported that 
intramuscular gene transfer with VEGF-bound 
plasmids was able to improve motor and sensory 
function in a rabbit model who had peripheral 
ischemic neuropathy [26]. Besides, VEGF 
administration therapy in post-stroke patients can 
reduce the extent of cerebral infarction because 
VEGF will stimulate angiogenesis and neurogenesis 
in areas near the penumbra [27], [28].
 
The 
administration of specific antibodies to block the 
function of VEGF in injured animal models apparently 
can increase the size of the lesion and reduce 
angiogenic activity and astroglia in the striatum [29]. 
There are also other studies that support the 
role of VEGF in controlling damage from brain injury, 
for example, the administration of VEGF to spinal cord 
contusions can improve cellular levels, and the 
administration of VEGF significantly increases nerve 
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regeneration when the Matrigel implant is inserted into 
sciatic nerve injury [30], [31], [32]. 
Based on these findings, for example in 
models of stroke, diabetic neuropathy, and spinal cord 
injury, VEGF therapy significantly increases cellular 
and functional improvement, so it is reasonable that 
when a cellular injury occurs due to hypoxia, it 
appears that there is a decrease of VEGF expression. 
Another possibility of decreasing VEGF-A expression 
is the activity of Glia Cell-Derived Conditioned 
Medium (CM), both CM astrocytes and C6 CM glioma 
cells because in acute stroke there will be an increase 
in proliferation of glial cells, including astrocytes.  
Another theory that VEGF will increase its 
expression in the acute phase of brain injury so that it 
can affect endothelial permeability which results in 
cerebral oedema, for example in patients with acute 
stroke, is still controversial, and further research is 
needed with a focus on VEGF receptor activity that 
might answer the controversy.  
The limitations of this study were: (1) the 
activity of glial cells during hypoxic conditions is 
difficult to control, (2) the maximum time taken for 
taking blood in patients is 6 hours from the time of 
onset, and (3) the number of other variables that can 
affect VEGF-A expression in acute ischemic stroke 
group.  
It was concluded that the expression of 
VEGF-A in the acute ischemic stroke group was lower 
than in the non-ischemic stroke group.  
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